SIMPLAAFY was a multicenter, open-label trial that included 1,857 patients (mean age 76 years; 43% women) with AF who underwent LAAO with the Watchman FLX Pro device (Boston Scientific) without ...

The population was enriched with a sicker phenotype than prior trials, which may have enhanced the impact on hard outcomes.

The study showed notable sex-based differences, as well as a trend toward better survival in those who got an intervention.

The trial is “a turning point” in the management of moderate AS, says Philippe Généreux, adding that the disease is not benign.

The rates of TLF were considerably lower than the investigators expected, leading to questions about experience and selection ...

Using previously obtained CT scans, operators were able to plan procedures ahead of time, with no ill effects on outcome.

Immediate costs are higher for TAVI, but patients and the healthcare system benefit long-term from earlier intervention.

REMEDY-PILOT showed the safety and feasibility of using the device, but with no effects on perfusion or angina symptoms.

SAN DIEGO, CA—Patients treated with the Agent drug-coated balloon (DCB; Boston Scientific) have encouraging outcomes at 1 ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

The decrease in death/HF with a single subcutaneous injection of the novel GP IIb/IIIa inhibitor seen at 30 days persisted.

Experts hope the findings will bring awareness to the idea that it’s not only heat that matters for adverse cardiovascular ...